Clinical Trial Update: Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Incyte reports a completed phase 1/2 trial evaluating a three-drug immunotherapy combo (INCMGA00012 anti-PD-1, INCAGN02385 anti-LAG-3, INCAGN02390 anti-TIM-3) i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• INCAGN02385 (LAG-3 inhibitor)
• INCAGN02390 (TIM-3 inhibitor)
• INCMGA00012

Snippet

Sponsor: Incyte Corporation | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED